The potential impact of hematocrit correction on evaluation of tacrolimus target exposure in pediatric kidney transplant patients
Background Tacrolimus is an important immunosuppressive agent with high intra- and inter-individual pharmacokinetic variability and a narrow therapeutic index. As tacrolimus extensively accumulates in erythrocytes, hematocrit is a key factor in the interpretation of tacrolimus whole blood concentrations. However, as hematocrit values in pediatric kidney transplant patients are highly variable after kidney transplantation, translating whole blood concentration targets without taking hematocrit into consideration is theoretically incorrect. The aim of this study is to evaluate the potential impact of hematocrit correction on tacrolimus target exposure in pediatric kidney transplant patients. Methods Data were obtained from 36 pediatric kidney transplant patients. Two hundred fifty-five tacrolimus whole blood samples were available, together responsible for 36 area under the concentration-time curves (AUCs) and trough concentrations. First, hematocrit corrected concentrations were derived using a formula describing the relationship between whole blood concentrations, hematocrit, and plasma concentrations. Subsequently, target exposure was evaluated using the converted plasma target concentrations. Ultimately, differences in interpretation of target exposure were identified and evaluated. Results In total, 92% of our patients had lower hematocrit (median 0.29) than the reference value of adult kidney transplant patients. A different evaluation of target exposure for either trough level, AUC, or both was defined in 42% of our patients, when applying hematocrit corrected concentrations. Conclusion A critical role for hematocrit in therapeutic drug monitoring of tacrolimus in pediatric kidney transplant patients is suggested in this study. Therefore, we believe that hematocrit correction could be a step towards improvement of tacrolimus dose individualization.
|Keywords||Therapeutic drug monitoring (TDM) . Tacrolimus . Hematocrit . Pediatrics . Kidney transplantation|
|Persistent URL||dx.doi.org/10.1007/s00467-018-4117-x, hdl.handle.net/1765/114995|
Schijvens, A.M., van Hesteren, F.H.S., Cornelissen, E.A.M, Bootsma-Robroeks, C., Brüggemann, M, Burger, D.M, … Ter Heine, R. (2019). The potential impact of hematocrit correction on evaluation of tacrolimus target exposure in pediatric kidney transplant patients. Pediatric Nephrology, 34(3), 507–515. doi:10.1007/s00467-018-4117-x